Related references
Note: Only part of the references are listed.Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke et al.
CANCERS (2021)
Structure-activity relationships for binding of 4-substituted triazole-phenols to macrophage migration inhibitory factor (MIF)
Zhangping Xiao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?
Eugenio Cavalli et al.
MOLECULES (2020)
Two-hit wonders: The expanding universe of multitargeting epigenetic agents
Angel R. de Lera et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2020)
Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer
Bin Liu et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
7-Hydroxycoumarins Are Affinity-Based Fluorescent Probes for Competitive Binding Studies of Macrophage Migration Inhibitory Factor
Zhangping Xiao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Joshua P. Smalley et al.
MOLECULES (2020)
MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential
Justin C. Penticuff et al.
NATURE REVIEWS UROLOGY (2019)
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Junting Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor
Bin Liu et al.
CANCERS (2019)
Dual or multi-targeting inhibitors: The next generation anticancer agents
Nulgumnalli Manjunathaiah Raghavendra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives
Hai-Tao Qin et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Elisabeth Hessmann et al.
GUT (2017)
Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
Rong-geng Fu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature
A. J. van der Wekken et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets
Nadege Kindt et al.
ONCOLOGY LETTERS (2016)
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Macrophage Migration Inhibitory Factor Limits Activation-Induced Apoptosis of Platelets via CXCR7-Dependent Akt Signaling
Madhumita Chatterjee et al.
CIRCULATION RESEARCH (2014)
Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases
Frank J. Dekker et al.
DRUG DISCOVERY TODAY (2014)
Macrophage Migration Inhibitory Factor (MIF) Enzymatic Activity and Lung Cancer
Leona Mawhinney et al.
MOLECULAR MEDICINE (2014)
Functional disruption of macrophage migration inhibitory factor (MIF) suppresses proliferation of human H460 lung cancer cells by caspase-dependent apoptosis
Yubiao Guo et al.
CANCER CELL INTERNATIONAL (2013)
Shifting from the single to the multitarget paradigm in drug discovery
Jose L. Medina-Franco et al.
DRUG DISCOVERY TODAY (2013)
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
Genevieve P. Delcuve et al.
CLINICAL EPIGENETICS (2012)
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)
S. E. Witta et al.
ANNALS OF ONCOLOGY (2009)
Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1&COLRATIO;2)
David J. Witter et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis
X-X He et al.
GUT (2006)
Macrophage migration inhibitory factor: A regulator of innate immunity
T Calandra et al.
NATURE REVIEWS IMMUNOLOGY (2003)
Share Paper
